Novartis “At An Inflection Point,” Announces $5B Buyback

In a move that reinforces its commitment to enhance returns to shareholders, Novartis AG (ADR) (NYSE:NVS) announced it will buy back shares worth $5B over the next two years, commencing immediately. Novartis has reached an inflection point “Novartis AG (ADR) (NYSE:NVS) has reached an inflection point, having fully integrated Alcon and reduced debt,” said Joseph Jimenez, CEO of Novartis. “We are now further sharpening the execution of our strategy to strengthen shareholder value through science-based innovation in high-growth segments of healthcare where we have the global scale, competitive advantage and the right capabilities to win.” Also see: Roche ‘extremely open’ to…